|
|
Vaccine Detail
|
WT1 Peptide Vaccine OCV-501 |
| Vaccine Information |
- Vaccine Name: WT1 Peptide Vaccine OCV-501
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007076
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: OCV-501 is a helper peptide derived from the WT1 protein (Kobayashi et al., 2017).
- Description: AThis is for Leukemia Cancer (NCT01961882). peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors (Kobayashi et al., 2017; NCIT_C106257).
|
| Host Response |
|
|
| References |
Kobayashi et al., 2017: Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y. A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia. Cancer immunology, immunotherapy : CII. 2017; 66(7); 851-863. [PubMed: 28321480].
NCIT_C106257: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106257]
NCT01961882: [https://clinicaltrials.gov/show/NCT01961882/]
|
|
